2021-11-15T06:53:51-05:00 2020-12-31 205732491 BRANDON ACCOUNTING SERVICES LLC 20988 NEGRIL COURT Lutz FL 33558 990 2020-01-01 473290570 GLOBAL ALZHEIMERS PLATFORM FOUNDATION INC GLOB 1101 K STREET NW STE 400 Washington DC 20005 JOHN DWYER PRESIDENT 3109809702 2021-11-12 true JOHN DWYER XXX-XX-XXXX JAMES H BRANDON P00102973 3014522111 2021-11-15 0 00 AAL1 IAL1 2020 2022-09-23 18:48:47Z JOHN DWYER 5393061 false X www.globalalzplatform.org X 2015 DC TO JOIN TOGETHER LEADING ACADEMIC RESEARCHERS, PHARMACEUTICAL COMPANIES NONPROFIT ORGANIZATIONS, FOUNDATIONS AND GOVERNMENTS WORLDWIDE TO REDUCE TIME, COST AND RISK OF ALZHEIMERS CLINICAL TRIALS IN ORDER TO SPEED INNOVATIVE MEDICINES TO THOSE WITH OR AT RISK OF ALZHEIMERS 7 7 14 0 0 4788807 5393061 0 0 0 4788807 5393061 505600 130500 0 0 0 6735 6050464 5414446 6556064 5544946 -1767257 -151885 1362080 1076430 1655896 1525632 -293816 -449202 TO JOIN TOGETHER LEADING ACADEMIC RESEARCHERS, PHARMACEUTICAL COMPANIES NONPROFIT ORGANIZATIONS, FOUNDATIONS AND GOVERNMENTS WORLDWIDE TO REDUCE TIME, COST AND RISK OF ALZHEIMERS CLINICAL TRIALS IN ORDER TO SPEED INNOVATIVE MEDICINES TO THOSE WITH OR AT RISK OF ALZHEIMERS false false 4083499 THE ORGANIZATION IS ESTABLISHING A STANDING GLOBAL TRIAL-READY PLATFORM TO DRIVE QUALITY, EFFICIENCY, AND INNOVATION IN ALZHEIMERS CLINICAL TRIALS, SEEKING TO REDUCE CLINICAL TESTING CYCLE TIMES BY TWO YEARS AND TO ACHIEVE GREATER UNIFORMITY IN TRIAL POPULATIONS. IT IS DOING THAT BY BUILDING LARGE, WELL-CHARACTERIZED TRIAL-READY COHORTS, AND A NETWORK OF CERTIFIED HIGH-PERFORMANCE CLINICAL TRIAL SITES. 4083499 true true false false false false false false false false true false false false true false false false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false true 15 0 false 14 true false false false false false false false false false false false false false false false false false X 7 7 false false false false false false false true true false false true true true true true true true true false X X THE ORGANIZATION 3014522111 1101 K STREET NW SUITE 400 Washington DC 20005 JOHN DWYER PRESIDENT AND CO-FOUNDER 40.00 0.00 X X 450920 0 0 PASCALE WITZ BOARD MEMBER 5.00 0.00 X 0 0 0 NEIL BUCKHOLTZ BOARD MEMBER 5.00 0.00 X 0 0 0 MICHAEL J GLOSSERMAN BOARD MEMBER 5.00 0.00 X 0 0 0 GEORGE VRADENBURG BOARD CHAIR 20.00 0.00 X 0 0 0 STEVEN PAUL FOUNDING BOARD MEMBER 5.00 0.00 X 0 0 0 DREW HOLZAPFEL FOUNDING BOARD MEMBER 5.00 0.00 X 0 0 0 450920 0 0 1 false true false RICHARD MOHS 1110 N LAKE SHORE DRIVE 19S CHICAGO IL 60611 CONSULTANT 202020 COGSTATE LTD GPO BOX 2777 MELBOURNE MELBOURNE VIC AS 3001 PROJECT MANAGMENT 334715 RATIONAL 360 1828 L STREET NE 640 Washington DC 20036 PUBLIC RELATIONS 245480 PINTAIL SOLUTIONS LLC 40 CRICKETT KNOLL LA Carmel IN 46033 PROGRAM MGMT 1039361 4 5393061 5393061 5393061 0 0 0 X 130500 130500 3980642 3473779 506863 112098 112098 157234 157234 128327 128327 250301 250301 15995 1052 14943 11435 11435 DESIGN AND MARKETING 6735 6735 ADMINISTRATIVE SUPPORT 87850 87850 CONSULTANTS 185661 185661 478168 478168 5544946 4083499 1454712 6735 980133 300147 374219 767732 4217 5061 6030 2540 3511 3490 1362080 1076430 645896 561555 1010000 500000 232277 231800 1655896 1525632 X -293816 -449202 -293816 -449202 1362080 1076430 X -151885 -3501 X false true X true false X 3050000 4250341 6427457 4788807 3550277 22066882 3050000 4250341 6427457 4788807 3550277 22066882 11220134 10846748 14 14 22066896 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 6030 2540 3490 3490 TRADEMARKS WEB SITE DUE TO AFFILIATE 231800 231800 X X X false false false false false false false false false JOHN DWYER PRESIDENT AND CO-FOUNDER 450920 450920 Form 990 governing body review Part VI line 11 THE FORM 990 WAS REVIEWED BY ONE OF THE DIRECTORS AND CHIEF EXECUTIVE OFFICER. A COPY WAS PROVIDED TO THE ORGANIZATIONS GOVERNING BODY BEFORE IT WAS FILED WITH THE IRS. Conflict of interest policy compliance Part VI line 12c EACH DIRECTOR, PRINCIPAL OFFICER AND MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS ANNUALLY SIGNS A STATEMENT WHICH AFFIRMS THAT EACH HAS 1) RECEIVIED A COPY OF THE CONFLICTS OF INTEREST POLICY; 2) HAS READ AND UNDERSTANDS THE POLICY; 3) HAS AGREED TO COMPLY WITH THE POLICY; AND LASTLY, UNDERSTANDS THAT THE ORGANIZATION IS A NON-PROFIT PUBLIC BENEFIT CORPORATION AND, IN ORDER TO MAINTAIN ITS FEDERAL EXEMPTION, IT MUST ENGAGE PRIMARILY IN ACTIVITIES WHICH ACCOMPLISH ONE OR MORE OF ITS TAX-EXEMPT PURPOSES CEO executive director top management comp Part VI line 15a THE BOARD HAS A COMPENSATION COMMITTEE THAT MEETS TO REVIEW AND APPROVE COMPENSATION POLICIES AND COMPENSATION PLANS FOR OFFICERS. OFFICER COMPENSATION PLANS ARE REVIEWED AND COMPARED TO COMPARABLE MARKET DATA, ENVIRONMENTAL CONDITIONS AND OTHER IMPACTFUL CRITERIA. Other officer or key employee compensation Part VI line 15b THE BOARD HAS A COMPENSATION COMMITTEE THAT MEETS TO REVIEW AND APPROVE COMPENSATION POLICIES AND COMPENSATION PLANS FOR OFFICERS. OFFICER COMPENSATION PLANS ARE REVIEWED AND COMPARED TO COMPARABLE MARKET DATA, ENVIRONMENTAL CONDITIONS AND OTHER IMPACTFUL CRITERIA. Form 990 availability to public Part VI line 18 THE ORGANIZATION ALLOWS FOR NORMAL REVIEW OF ITS FORM 990 DURING NORMAL BUSINESS HOURS. Governing documents etc available to public Part VI line 19 THE ORGANIZATION MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLCY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. Explanation of other changes in net assets or fund balances Part XI line 9 PRIOR PERIOD ADJUSTMENT FOR AMORTIZATION EXPENSE, 78404 PRIOR PERIOD ADJUSTMENT, 3,501 List of other expenses Part IX line 24e REGISTRY INFORMATICS DATA MANAGEMENT 148,268PUBLIC RELATIONS 311,051CONSULTANTS 18,849TOTAL OTHER PROGRAM SERVICE EXPENSE 478,168 General explanation attachment MISSION -TO JOIN TOGETHER LEADING ACADEMIC RESEARCHERS, PHARMACEUTICAL COMPANIES, NONPROFIT ORGANIZATIONS AND FOUNDATIONS, AND GOVERNMENTS AROUND THE WORLD TO REDUCE THE TIME, COST AND RISK OF ALZHEIMERS CLINICAL TRIALS IN ORDER TO SPEED INNOVATIVE MEDICINES TO THOSE WITH OR AT RISK OF ALZHEIMERS DISEASE.